A Darzalex-based regiment improved MRD negativity rates while sustaining MRD negativity compared with VRd in patients with ...

Updated findings from the PERSEUS study found that patients with newly diagnosed multiple myeloma benefited from a treatment ...

Among patients who became MRD negative at a 10-5 sensitivity, 38.6% in the D-VRd arm had sustained MRD negativity vs 17.4% in the control arm (P = .0006). At the 10 -6 sensitivity, these ...

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) a biotech company developing the industry’s leading ...

Telo's MRD clinical trials with McGill University have two objectives that will potentially enable the development of two prognostic tests for monitoring myeloma MRD. The two objectives include ...

Japan’s MHLW accepts for review GSK’s NDA for Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Wednesday, September 18, 2024, 10:00 Hrs [IST] GSK plc a ...

China’s NMPA granted BTD for Blenrep (belantamab mafodotin) combined with BorDex for the treatment of multiple myeloma.

GSK’s Blenrep in combo with BorDex receives China NMPA breakthrough therapy designation to treat relapsed/refractory multiple myeloma: London, UK Saturday, September 14, 2024, 0 ...

transplant-eligible patients with multiple myeloma. The IsKia trial showed that 77% of the Sarclisa group achieved minimal residual disease (MRD) negativity at the end of the induction and ...